EcoDrugPlus

60s Ribosomal Protein L19-Like

Ensembl ID : ENSBSLG00000025688
Gene Symbol: LOC114846422
3 Cross references
321 Possible Orthologues:

60s Ribosomal Protein L22

Ensembl ID : ENSBSLG00000000796
Gene Symbol: LOC114855423
2 Cross references
371 Possible Orthologues:

60s Ribosomal Protein L22

Ensembl ID : ENSBSLG00000016985
Gene Symbol: LOC114859321
3 Cross references
384 Possible Orthologues:

60s Ribosomal Protein L26

Ensembl ID : ENSBSLG00000024385
Gene Symbol: LOC114864771
3 Cross references
477 Possible Orthologues:

60s Ribosomal Protein L3

Ensembl ID : ENSBSLG00000013017
Gene Symbol: LOC114860783
3 Cross references
338 Possible Orthologues:

60s Ribosomal Protein L4-A-Like

Ensembl ID : ENSBSLG00000016291
Gene Symbol: LOC114857279
3 Cross references
340 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSBSLG00000012314
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSBSLG00000026081
Gene Symbol: ADAM17
3 Cross references
209 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSBSLG00000014345
Gene Symbol: ADAM17
3 Cross references
210 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSBSLG00000001313
Gene Symbol: ADAMTS5
3 Cross references
199 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSBSLG00000023447
Gene Symbol: ADRM1
3 Cross references
193 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSBSLG00000014881
Gene Symbol: AKT1
3 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).